sample. This could explain the divergent results described in the literature. Serum PTH in 14 proven cases of primary hyperparathyroidism was 49-808 (median 111) ng/L, undetectable (<5 ng/L) in 10 cases of primary hypoparathyroidism and in 10 cases of hypercalcemia associated with malignancy, compared with 7-39 ng/L in 45 normal subjects. PTH was 9 to 19 ng/L in four patients with familial benign hypercalcemia. In 39 patients with renal failure, apparent concentrations were 14 to 857 (median 133) ng/L, but sera from these patients pre-diluted with zero standard did not parallel dilutions of the standard, PTH 1-84. PTH concentrations were not significantly decreased in blood or serum kept at 20 #{176}C for up to 6 h. After successful removal of a parathyroid adenoma, the mean half-time for disappearance of PTH in vivo in five hyperparathyroid patients was 3.3 mm.
We investigated a broad series of final concentrations of sialidase from this source (0.6 to 139 U/L; substrate, sialyl lactose) in the incubation mixture, but found no improved separation as compared with non-pretreated samples.
Discussion
We have confirmed that the electrophoretic resolution of bone and liver AP fractions can be specifically improved by pretreating serum samples with sialidase (1). This method was introduced with sialidase from Vibrio cholerae (1). Later, sialidases from other sources (e.g., from Clostridium peifringens) were used for this purpose, but resulted in some disappointments (2). Our findings show that the electrophoretic separation is decisively determined by the type of sialidase used in the preincubation with serum
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sample. This could explain the divergent results described in the literature.
We obtained the best resolution of both AP fractions with sialidase from Vibrio cholerae. In addition, different activity concentrations must be used with the different sialidases. This and the fact that sialidase from Arthrobacter ureafaciens is not suited for this method suggest that the different types of this enzyme vary in their ability to catalyze digestion of the terminal sialic acid residues in AP fractions, but that their different digestion capacities cannot be inferred from the usual activity measurements with mucin or sialyl lactose. However, a standardized method of sialidase activity determination as we applied it would simplify the matter, avoiding an inconvenient number of incubation experiments with different concentrations of sialidase to determine the best activity concentration for use in electrophoretic separation.
Serum PTH in 14 proven cases of primary hyperparathyroidism was 49-808 (median 111) ng/L, undetectable (<5 ng/L) in 10 cases of primary hypoparathyroidism and in 10 cases of hypercalcemia associated with malignancy, compared with 7-39 ng/L in 45 normal subjects. PTH was 9 to 19 ng/L in four patients with familial benign hypercalcemia. In 39 patients with renal failure, apparent concentrations were 14 to 857 (median 133) ng/L, but sera from these patients pre-diluted with zero standard did not parallel dilutions of the standard, PTH 1-84. PTH concentrations were not significantly decreased in blood or serum kept at 20 #{176}C for up to 6 h. After successful removal of a parathyroid adenoma, the mean half-time for disappearance of PTH in vivo in five hyperparathyroid patients was 3.3 mm.
The development of two-site immunometric assays for parathyrin (PTH) represents a new generation of immunoassays for use in investigating disorders of calcium metabolism. These assays may offer significant advantages over conventional RIA methods in terms of analytical performance, laboratory practice, and clinical discrimination (1) (2) (3) . The design of immunometric assays confers a lower detection limit than is currently achieved by most RIAs (4, 5), which should improve the discrimination of hormone concentrations in normal and hyperparathyroid patients, and the identification of patients with suppressed or subnormal PTH concentrations. Specificity is improved by the use of two antisera directed to different regions of the molecule, allowing measurement of"intact" P'FH in the presence of fragments, which constitute most of the circulating PTH-related peptides in many pathological conditions (6, 7).
We report here the analytical performance of an immunoradiometric assay (IRMA) of PTH in routine practice, together with the discrimination achieved in defined groups of patients with disorders of calcium metabolism. We examined the stability of PTH in serum and blood to identify suitable conditions for handling specimens before assay. We also studied the rate of disappearance of PTH from serum in vivo after removal of a parathyroid adenoma, to determine the half-life of intact PTH.
Materials and Methods

PTH Assay
"N-tact" PTH IRMA kits were obtained from INCSTAR Ltd., Berkshire, RG11 5AB, U.K. In this direct, two-site IRMA, 200 L of unknown serum or human-serum-based standard is incubated with 100 L of 1251-labeled, affinitypurified antiserum specific for PTH 1-34, and with a polystyrene bead coated with affinity-purified antiserum specific for P'I'H 39-84. The recommended incubation conditions are 22 h at 20-25 #{176}C without agitation (option A) or 4 h at 20-25 #{176}C with agitation (option B). The bead is then washed three times with 1-mL portions of wash solution, and the radioactivity bound to the bead is counted. In the present study we used polystyrene assay tubes, rather than the borosilicate glass recommended by the manufacturers, and we followed option A for all assay incubations. We used a "Star 700" sample processor (IDS Ltd., Tyne and Wear, NE37 3HS, U.K.) to dispense the serum samples and automatically to wash the bead with a wash solution containing, per liter, 5 mmol of potassium phosphate, 76 mmol of sodium chloride, 2.5 mL of Tween 80 surfactant, and 0.1 g of sodium aside. PTH 44-68 and PTH 39-84 were obtained from Peninsula Laboratories, St. Helens, WA9 3AJ, U.K.
Radioactivity bound to the beads was counted for 2 mm in a Model 1261 gamma counter (Pharmacia, Milton Keynes, MK9 3HP, U.K.). "RiaCalc" software was used for data reduction.
Curve fitting of standards was by spline function, and imprecision profiles were calculated from the error of duplicate determinations, with imprecision related to the concentration of the standards. The minimum detection limit calculated by RiaCalc is based on the 95% confidence limit of the zero standard.
Subjects
Blood was placed in polypropylene centrifuge tubes, containing plastic granules to aid separation (Sarstedt Ltd., Leicester, LE4 lAW, U.K.). Specimens from control subjects and patients were collected between 0900 and 1500 hours and the serum was separated within 1 and 2-3 h, respectively, then stored at -20 #{176}C until assay. Blood collected from patients with primary hyperparathyroidism, used for studies on the stability of endogenous PTH, was separated within 10 mm of collection. Specimens of blood were collected from a peripheral vein via an indwelling cannula before and at timed intervals after surgical removal of a parathyroid adenoma. Control subjects (n = 45; 22 male, 23 female) were normocalcemic laboratory staff and patients (mean age 34, range 12-50 y). Fourteen patients (three male, 11 female) had hypercalcemia (mean serum calcium 2.88, range 2.63-3.57 mmolfL) attributed to primary hyperparathyroidism, as was later confirmed by surgical removal of a parathyroid adenoma followed by normalization of values for serum calcium. 
Other Procedures
Stability of PTH. We studied the stability of endogenous PTH in blood and serum at ambient temperature by allowing aliquots of whole blood or serum (separated within 10 mm of venepuncture) to stand at 20 #{176}C for as long as 30 h before storage at -20 #{176}C, then assaying.
The effect of repeated freezing and thawing of serum (one, two, four, or six times) on measured concentrations of PTH was studied by using serum from six patients with proven or suspected hyperparathyroidism.
In each treatment cycle, serum was thawed at 20#{176}C for 1 h, then refrozen at -20 #{176}C for at least 4 h. Parallelism of dilutions of endogenous PTH. Immediately before assay, serum from four patients with primary hyperparathyroidism and five patients with chronic renal failure was diluted two-, four-, or eightfold with the zero standard in a matrix of human serum.
Statistics. Data were log-transformed before two-or three-way analysis of variance. The error variance generated was used to compare individual means by Student's t-test, adjusted according to the Bonferroni method for multiple comparisons (8). Table 1 . Sera from four patients with primary hyperparathyroidism were diluted two-, four-, and eightfold with zero standard. The mean PTH concentrations were 50%, 23%, and 10%, respectively, of the PTH concentration in undiluted serum. Sera from five patients with renal failure diluted in the same way gave mean P'FH concentrations of 62%, 34%, and 16%, respectively. The deviation from linearity was greatest (Figure 2 ) for the two patients with renal failure who had the highest apparent PT!! concentrations (549 and 564 ngfL).
Results
We investigated the cross-reaction by C-terminal fragments of PT!! by adding PTH 44-68 or FF11 39-84 to serum from a patient with primary hyperparathyroidism and a serum FF11 concentration of 135 ng/L. After addition of 12.5, 25, or 50 pg of PT!! 44-68 per liter, the FF11 concentrations measured in serum were 139, 136, and 124 ng/L, respectively; after addition of 12.5, 25, or 50 tgfL of PTH 39-84, the PTH concentrations measured in serum were 128, 124, and 117 ngfL, respectively. FFH concentrations were not significantly decreased when blood or serum was left standing at 20 #{176}C for up to 6 h ( Table 2) . Analysis of the overall data revealed significantly higher FF11 concentrations for specimens of blood rather than serum (P <0.001), although this was not significant at individual time points. Sera from six patients with proven or suspected primary hyperparathyroidism ,.=.
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Discussion
We found the mean detection limit of the N-tact PT!! mxt to be 4 ngJL, higher than that (1.2 ng/L) quoted by the manufacturer. Variations in the detection limit (from 1.4 to 10 ng/L) mainly reflected assay imprecision and affected the discrimination achieved between normal and low or suppressed FF11 concentrations in different assays. Good within-and between-batch imprecision was achieved in routine practice, superior to that for most RIA methods (4, 9) or for a chemiluminometric assay (10).
Although dilution studies on unknown samples were found by the manufacturers to be satisfactory, we found non-parallelism on dilution of serum from renal patients, which appeared to be greatest in those patients with the highest serum PTH concentrations.
The increase in apparent PTH measured on dilution of serum suggested that interference in the assay might relate to the high concentrations of C-terminal fragments in these patients (7). This was confirmed by demonstrating that the addition of PT!! 44-68 and PT!! 39-84 to serum in concentrations similar to those found in renal failure (9) gave a significantly lower value for measured PTH concentration.
These findings
suggest that use of the N-tact PTH mr for renal patients may not be valid, depending on the relative concentrations of intact FF11 and C-terminal fragments. A substantial pre-dilution of the serum sample with zero-standard matrix may provide more nearly accurate results in these patients.
FFH was stable in both blood and serum for at least 6 h, with 80% and 64%, respectively, remaining after 24 h. In contrast, in a previous study in which the "Allegro" IRMA (Nichols Institute, San Juan Capistrano, CA) was used, PTH was found to be less stable in blood than in serum, with 68% and 88%, respectively, remaining after 18 h at 23 #{176}C; the losses could be partly prevented by aprotinin (3). Compared with endogenous hormone, FF11 1-84 added to serum or present in serum-based standards has been found to be less stable at ambient temperature (3, 11), suggesting that endogenous PTH is preferable for quality-control pools. The stability of intact FF11 to freezing and thawing up to four times allows specimens to be assayed on more than one occasion if required.
The range of PT!! concentrations we found for normal subjects (7-39 ng/L) is similar to that found by INCSTAR when we used option A, 7-33 ng/L (12), although lower than the suggested range in the product insert (10-55 ng/L). Others have found intact PT!! reference intervals of 10-55 ng/L by Allegro IRMA (3), or 10-100 ngfL by a chemiluminometric method (2). In primary hyperparathyroidism, none of the proven cases and three of the suspected cases had serum P'FH concentrations within the range found in control subjects. Other groups using twosite assays have also reported a small overlap in PT!! concentrations in controls and proven and (or) suspected hyperparathyroidism (1, 3), although the discrimination achieved is nevertheless superior to that provided by most RIA methods (5, 8, 13 ). One patient with hyperparathyroidism excluded from the results of the present study had a history of renal stones, and several months previously had increased values for serum calcium (2.75 mmol/L) and PT!! (by RIA). However, on the day before surgery, values for serum calcium (2.47 mmol/L) and intact FF11 (26 ngfL) were not above normal, although a typical parathyroid adenoma was removed at surgery and confirmed by histology. Intermittent hypercalcemia occasionally occurs in hyperparathyroidism at least in this case, to be due to intermittent oversecretion of FF11. Serum PT!! by other two-site immunoassays has been found to be undetectable, subnormal, or normal in hypercalcemic patients with malignancy or FF11-independent causes of hypercalcemia (1-3) . We found undetectable serum PT!! (<5 ng/L) in 10 patients with various malignancies, which may reflect differences in the patients studied and (or) differences in the specificity of the assays. It now seems likely that the hypercalcemia of malignancy may result from the production by the tumor of the recently identified protein, FF11-related protein (15) ; this should in turn lead to suppressed values for FFH, as we found in the present study. Although there is a high degree of homology in the first 13 amino acids of PT!! and PTH-related protein, which might lead to both peptides being recognized by an antibody raised to PTH 1-34, there is little C-terminal homology. Thus the antibody to PT!! 39-84 used to coat the polystyrene bead would not be expected to cross-react with P'FH-related protein.
Patients with the rare condition, familial benign hypercalcemia, had normal values for P'FH, whereas conventional RIA methods have consistently failed to discriminate reliably between PT!! concentrations in familial benign hypercalcemia and primary hyperparathyroidism (16). Of our 39 patients with renal failure, 37 had increased FF11 in serum, suggesting that many continue to have secondary hyperparathyroidism despite the frequent use of measures to suppress this. However, the parallelism studies on serum from renal failure patients suggested that the FFH concentration measured in undiluted serum may underestimate the true concentration in these patients. The half-time for disappearance of FF11 after removal of a parathyroid adenoma was 3.3 mm, which agrees well with a previous estimate of rate of disappearance of endogenous or exogenous FF11 as determined by an RIA with N112-terminal specificity (17) . This suggests that We conclude that the N-tact PTH IRMA offers reliable diagnostic accuracy in distinguishing PTH-dependent and -independent causes of hypercalcemia and appears to measure the bioactive form(s) of the hormone in primary hyperparathyroidism.
